Ubiquinon (Coenzyme Q10) Application After Gingival Recession Coverage
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This randomised double blinded clinical trial has the aim to assess the effect of Ubiquinon
(Coenzyme Q10) on early wound healing following gingival recession coverage. Coenzyme Q10
(CoQ10) is a critical intermediate of the mitochondrial electron transport chain for the
synthesis of adenosine triphosphate. The biological importance of CoQ10 is related to
antioxidant activity, which can scavenge free radicals as well as restore the antioxidant
defence system. Both in vitro and animal studies have suggested that CoQ10 acts as
anti-inflammatory agent reducing the inflammatory response by inhibiting the translocation of
nuclear factor kappa beta into the nucleus.
Gingival recessions particularly in the esthetic area have become a common indication for
treatment. The use of subepithelial palatal connective tissue graft (SCTG) in conjunction
with either a coronally advanced flap (CAF) or a coronally advanced tunnel are well
established techniques for both the treatment of single and multiple gingival recessions.
Interestingly, despite the fact that CoQ10 is widely investigated, virtually no information
exists on its effects upon early wound healing of oral tissues. Therefore, the aim of this
study is to investigate the effect of CoQ10 on wound healing after gingival recession
surgery.